REGINfo: GALAPAGOS - Pharmacie - Financial information

SEARCH BY

Issuer directory

KEYWORDS

COMPANIES / ISIN

TYPE OF INFORMATION

INDUSTRY

ADVANCED SEARCH

COMPARTMENTS / INDICES

France

America

Asia

Oceania

> ASX 20
Australia - ASX 20
> NZX 15
New Zealand - NZX 15

Africa

> FTSE/JSE...
South Africa - FTSE/JSE Top 40
> TA 25
Israel - TA 25
- ALONY HETZ
- AZRIELI GROUP
- BAZAN
- BEZEQ
- DELEK DRILLIN
- DELEK GROUP
- DISCOUNT
- ELBIT SYSTEMS
- Energean Oil Gas
- FIBI BANK
- GAZIT GLOBE
- HAREL
- ICL
- IFF
- ISRAEL CORP
- LEUMI
- LivePerson
- MIZRAHI TEFAHOT
- NICE
- OPKO HEALTH
- ORMAT
- PAZ OIL
- PERRIGO
- Phoenix Group Holdings
- POALIM
- SHUFERSAL
- STRAUSS GROUP
- TEVA
- TOWER JAZZ

Europe

COMPANY SEARCH RESULT

$GALAPAGOS: Click to view the issuer\'s details$

Last update : 21/08/2018 >View issuer details

2021.08.05 | 22:01 | Permanent Information Releases / General Company News

puce Galapagos rapporteert financiële resultaten eerste halfjaar met geheroriënteerde pijplijn en operationele voortgang - HTML (w)

2021.08.05 | 22:01 | Permanent Information Releases / Sales and Revenues

puce Galapagos reports H1 financial results with refocused pipeline and operational progress - HTML (w)

2021.07.14 | 22:01 | Permanent Information Releases / General Company News

puce Galapagos meldt positieve resultaten met selectieve TYK2-remmer GLPG3667 in fase 1b-studie in psoriasis - HTML (w)

2021.07.14 | 22:01 | Permanent Information Releases / General Company News

puce Galapagos demonstrates early clinical activity with SIK2/3 inhibition in inflammation - HTML (w)

2021.07.14 | 22:01 | Permanent Information Releases / General Company News

puce Galapagos toont vroege klinische activiteit aan met SIK2/3-remmer bij ontstekingsziekten - HTML (w)

2021.07.14 | 22:01 | Permanent Information Releases / Sales and Revenues

puce Galapagos reports positive topline results with selective TYK2 inhibitor GLPG3667 in Phase 1b psoriasis study - HTML (w)

2021.07.10 | 11:10 | Permanent Information Releases / General Company News

puce Galapagos announces new data supporting rapid symptom improvement and sustained steroid-free remission with filgotinib in patients with Ulcerative Colitis - HTML (w)

2021.07.10 | 11:10 | Permanent Information Releases / General Company News

puce Galapagos maakt nieuwe data bekend die een snelle symptoomverbetering en aanhoudende steroïdvrije remissie met filgotinib bij patiënten met colitis ulcerosa ondersteunen - HTML (w)

2021.06.22 | 22:01 | Permanent Information Releases / General Company News

puce Galapagos announces departure of CSO Piet Wigerinck later this year - HTML (w)

2021.06.22 | 22:01 | Permanent Information Releases / General Company News

puce Galapagos kondigt vertrek van Chief Scientific Officer Piet Wigerinck aan later dit jaar - HTML (w)

2021.06.07 | 22:01 | Permanent Information Releases / General Company News

puce Galapagos increases share capital through subscription right exercises - HTML (w)

2021.06.07 | 22:01 | Permanent Information Releases / General Company News

puce Galapagos verhoogt kapitaal door uitoefening van inschrijvingsrechten - HTML (w)

2021.06.04 | 07:01 | Permanent Information Releases / General Company News

puce SELECTION study on filgotinib in ulcerative colitis published in The Lancet - HTML (w)

2021.06.04 | 07:01 | Permanent Information Releases / General Company News

puce SELECTION-studie naar filgotinib bij colitis ulcerosa, gepubliceerd in The Lancet - HTML (w)

2021.05.27 | 22:01 | Permanent Information Releases / General Company News

puce Galapagos to present data on rheumatoid arthritis at the upcoming European League Against Rheumatism (EULAR) congress - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 / Doc nb : 342